A 9 year, double blind study with 1,708 patients have shown significant evidence supporting EDTA chelation therapy for patients with coronary disease. The trial, known as TACT (Trial to Assess Chelation Therapy), was funded by the NIH (National Institute of Health) and sponsored by two of their institutes, the National Center for Complementary and Alternative Medicine and the National Heart Lung and Blood Institute.
“With a result that is likely to surprise and baffle much of the mainstream medical community, a large NIH-sponsored trial has turned up the first substantial evidence in support of chelation therapy for patients with coronary disease.” -Larry Husten, Forbes.com medical journalist
Contact us to learn more about oral chelation with Arizona Natural EDTA.